Published in J Biol Chem on June 09, 2011
Mitochondrial quality control: a matter of life and death for neurons. EMBO J (2012) 1.83
One ring to rule them all: trafficking of heme and heme synthesis intermediates in the metazoans. Biochim Biophys Acta (2012) 1.46
Multitasking in the mitochondrion by the ATP-dependent Lon protease. Biochim Biophys Acta (2011) 1.41
Phosphorylation of human TFAM in mitochondria impairs DNA binding and promotes degradation by the AAA+ Lon protease. Mol Cell (2012) 1.28
Clinically important features of porphyrin and heme metabolism and the porphyrias. Metabolites (2014) 1.19
Oxygen-sensitive mitochondrial accumulation of cystathionine β-synthase mediated by Lon protease. Proc Natl Acad Sci U S A (2013) 1.06
CODAS syndrome is associated with mutations of LONP1, encoding mitochondrial AAA+ Lon protease. Am J Hum Genet (2015) 1.02
Mitochondrial ClpX Activates a Key Enzyme for Heme Biosynthesis and Erythropoiesis. Cell (2015) 1.00
LON is the master protease that protects against protein aggregation in human mitochondria through direct degradation of misfolded proteins. Sci Rep (2015) 0.84
Circadian rhythms in acute intermittent porphyria--a pilot study. Eur J Clin Invest (2013) 0.82
Early life lead exposure causes gender-specific changes in the DNA methylation profile of DNA extracted from dried blood spots. Epigenomics (2015) 0.81
Protoporphyrin IX: the Good, the Bad, and the Ugly. J Pharmacol Exp Ther (2015) 0.80
A New Strategy for Production of 5-Aminolevulinic Acid in Recombinant Corynebacterium glutamicum with High Yield. Appl Environ Microbiol (2016) 0.79
Novel Mechanisms for Heme-dependent Degradation of ALAS1 Protein as a Component of Negative Feedback Regulation of Heme Biosynthesis. J Biol Chem (2016) 0.78
Genome-wide analysis reveals adaptation to high altitudes in Tibetan sheep. Sci Rep (2016) 0.77
ATP-Dependent Lon Protease Contributes to Helicobacter pylori-Induced Gastric Carcinogenesis. Neoplasia (2016) 0.77
Global analysis of posttranscriptional gene expression in response to sodium arsenite. Environ Health Perspect (2014) 0.76
Interindividual variation in gene expression responses and metabolite formation in acetaminophen-exposed primary human hepatocytes. Arch Toxicol (2015) 0.75
Mitochondrial Lon protease in human disease and aging: Including an etiologic classification of Lon-related diseases and disorders. Free Radic Biol Med (2016) 0.75
Heme status affects human hepatic messenger RNA and microRNA expression. World J Gastroenterol (2013) 0.75
Mutation in human CLPX elevates levels of δ-aminolevulinate synthase and protoporphyrin IX to promote erythropoietic protoporphyria. Proc Natl Acad Sci U S A (2017) 0.75
Selective degradation of mitochondria by mitophagy. Arch Biochem Biophys (2007) 8.24
Functional dissection and sequence of yeast HAP1 activator. Cell (1989) 3.56
Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell (2005) 3.54
Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med (2005) 2.95
Oxidative damage during aging targets mitochondrial aconitase. Proc Natl Acad Sci U S A (1997) 2.76
Effects by heme, insulin, and serum albumin on heme and protein synthesis in chick embryo liver cells cultured in a chemically defined medium, and a spectrofluorometric assay for porphyrin composition. J Biol Chem (1975) 2.47
Heme mediates derepression of Maf recognition element through direct binding to transcription repressor Bach1. EMBO J (2001) 2.32
Regulation by heme of mitochondrial protein transport through a conserved amino acid motif. Science (1993) 1.79
Cytochromes P450, drugs, and diseases. Mol Interv (2003) 1.66
Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by intravenous infusions of hematin. Proc Natl Acad Sci U S A (1971) 1.33
Regulation of 5-aminolevulinate synthase mRNA in different rat tissues. J Biol Chem (1988) 1.28
Towards the control of intracellular protein turnover: mitochondrial Lon protease inhibitors versus proteasome inhibitors. Biochimie (2007) 1.06
Nuclear receptors constitutive androstane receptor and pregnane X receptor activate a drug-responsive enhancer of the murine 5-aminolevulinic acid synthase gene. J Biol Chem (2003) 1.03
Iron increases HMOX1 and decreases hepatitis C viral expression in HCV-expressing cells. World J Gastroenterol (2009) 1.02
Regulated protein degradation in mitochondria. Experientia (1996) 0.95
Regulation of the stability of chicken embryo liver delta-aminolevulinate synthase mRNA by hemin. Biochem Biophys Res Commun (1989) 0.94
Heme regulates hepatic 5-aminolevulinate synthase mRNA expression by decreasing mRNA half-life and not by altering its rate of transcription. Arch Biochem Biophys (1991) 0.93
Enzymatic defects in porphyria: an overview. Semin Liver Dis (1982) 0.92
Inhibition by hemin of in vitro translocation of chicken liver delta-aminolevulinate synthase into mitochondria. Biochem Biophys Res Commun (1983) 0.92
Differential regulation of human ALAS1 mRNA and protein levels by heme and cobalt protoporphyrin. Mol Cell Biochem (2008) 0.91
Cytochrome P450 regulation: the interplay between its heme and apoprotein moieties in synthesis, assembly, repair, and disposal. Drug Metab Rev (2010) 0.90
Identification of the xenosensors regulating human 5-aminolevulinate synthase. Proc Natl Acad Sci U S A (2004) 0.89
Haeme-regulated degradation of delta-aminolevulinate synthase 1 in rat liver mitochondria. J Biochem (2007) 0.87
Endo-xenobiotic crosstalk and the regulation of cytochromes P450. Drug Metab Rev (2007) 0.86
Regulation of heme metabolism in rat hepatocytes and hepatocyte cell lines: delta-aminolevulinic acid synthase and heme oxygenase are regulated by different heme-dependent mechanisms. Arch Biochem Biophys (2000) 0.86
Haem repression of the housekeeping 5-aminolaevulinic acid synthase gene in the hepatoma cell line LMH. Biochem J (2005) 0.84
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
High-efficiency TALEN-based gene editing produces disease-resistant rice. Nat Biotechnol (2012) 3.61
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res (2008) 3.36
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology (2013) 3.13
Radiation-mediated proteolysis of CDT1 by CUL4-ROC1 and CSN complexes constitutes a new checkpoint. Nat Cell Biol (2003) 3.04
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med (2005) 2.95
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology (2012) 2.61
Control of DNA replication and chromosome ploidy by geminin and cyclin A. Mol Cell Biol (2002) 2.47
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
Mixer-settler counter-current chromatography with a barricaded spiral disk assembly with glass beads. J Chromatogr A (2007) 2.36
Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin. FASEB J (2006) 2.16
Rice xa13 recessive resistance to bacterial blight is defeated by induction of the disease susceptibility gene Os-11N3. Plant Cell (2010) 2.15
Hepatitis C, porphyria cutanea tarda and liver iron: an update. Liver Int (2012) 2.10
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (2008) 2.02
Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med (2006) 1.95
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
Extranodal NK/T-cell lymphoma, nasal type: a report of 73 cases at MD Anderson Cancer Center. Am J Surg Pathol (2013) 1.84
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl (2005) 1.76
Primary cirrhotic hepatocytes resist TGFbeta-induced apoptosis through a ROS-dependent mechanism. J Hepatol (2004) 1.72
Chronic ethanol feeding accelerates hepatocellular carcinoma progression in a sex-dependent manner in a mouse model of hepatocarcinogenesis. Alcohol Clin Exp Res (2011) 1.72
Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review. Hepatology (2010) 1.71
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
Hereditary hemochromatosis: time for targeted screening. Ann Intern Med (2008) 1.60
Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology (2007) 1.59
TRF2 promotes multidrug resistance in gastric cancer cells. Cancer Biol Ther (2006) 1.57
Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents. Proc Natl Acad Sci U S A (2010) 1.57
Involvement of CUL4 ubiquitin E3 ligases in regulating CDK inhibitors Dacapo/p27Kip1 and cyclin E degradation. Cell Cycle (2006) 1.51
The Characteristics and Significance of Locally Infiltrating B Cells in Lupus Nephritis and Their Association with Local BAFF Expression. Int J Rheumatol (2013) 1.51
A Legionella type IV effector activates the NF-kappaB pathway by phosphorylating the IkappaB family of inhibitors. Proc Natl Acad Sci U S A (2009) 1.48
MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology (2010) 1.38
ABCG15 encodes an ABC transporter protein, and is essential for post-meiotic anther and pollen exine development in rice. Plant Cell Physiol (2012) 1.37
Drug-induced liver injury associated with statins. Semin Liver Dis (2009) 1.36
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
Catechins in dietary supplements and hepatotoxicity. Dig Dis Sci (2013) 1.31
CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res (2009) 1.27
Alcohol and liver cancer. Alcohol (2005) 1.26
MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem Biophys Res Commun (2013) 1.25
Iron in nonhemochromatotic liver disorders. Semin Liver Dis (2005) 1.25
Role of alcohol in liver carcinogenesis. Semin Liver Dis (2009) 1.23
Role of Bach-1 in regulation of heme oxygenase-1 in human liver cells: insights from studies with small interfering RNAS. J Biol Chem (2004) 1.22
A proteome reference map and proteomic analysis of Bifidobacterium longum NCC2705. Mol Cell Proteomics (2006) 1.22
miR-132 regulates the differentiation of dopamine neurons by directly targeting Nurr1 expression. J Cell Sci (2012) 1.21
Serum measures of iron status and HFE gene mutations in patients with hepatitis B virus infection. Hepatol Res (2007) 1.20
Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis (2006) 1.19
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology (2014) 1.19
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology (2009) 1.18
Inhibition of phosphatidylinositol 3-kinase signaling in hepatic stellate cells blocks the progression of hepatic fibrosis. Hepatology (2009) 1.17
Golgi apparatus and neurodegenerative diseases. Int J Dev Neurosci (2008) 1.16
microRNAs: fad or future of liver disease. World J Gastroenterol (2011) 1.15
Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China. Arch Dermatol (2005) 1.14
HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology (2006) 1.13
Oxidative stress protection and the repair response to hydrogen peroxide in the hyperthermophilic archaeon Pyrococcus furiosus and in related species. Arch Microbiol (2010) 1.13
Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology (2010) 1.12
Synergistic protective effect of picroside II and NGF on PC12 cells against oxidative stress induced by H2O2. Pharmacol Rep (2007) 1.12
Stationary phase retention and preliminary application of a spiral disk assembly designed for high-speed counter-current chromatography. J Chromatogr A (2008) 1.12
The role of p70S6K in hepatic stellate cell collagen gene expression and cell proliferation. J Biol Chem (2005) 1.11
Rodent models of alcoholic liver disease: of mice and men. Alcohol (2012) 1.11
Salvianolic acid B prevents bone loss in prednisone-treated rats through stimulation of osteogenesis and bone marrow angiogenesis. PLoS One (2012) 1.11
Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol (2013) 1.10
HCV proteins increase expression of heme oxygenase-1 (HO-1) and decrease expression of Bach1 in human hepatoma cells. J Hepatol (2006) 1.10
Immunohistochemical detection of mutations in the epidermal growth factor receptor gene in lung adenocarcinomas using mutation-specific antibodies. Diagn Pathol (2013) 1.09
Co-up-regulation of three P450 genes in response to permethrin exposure in permethrin resistant house flies, Musca domestica. BMC Physiol (2008) 1.09
VSTM1-v2, a novel soluble glycoprotein, promotes the differentiation and activation of Th17 cells. Cell Immunol (2012) 1.09
Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology (2009) 1.08
The let-7 microRNA enhances heme oxygenase-1 by suppressing Bach1 and attenuates oxidant injury in human hepatocytes. Biochim Biophys Acta (2012) 1.08
Bis{1-[(1H-benzimidazol-2-yl)meth-yl]-1H-imidazole-κN}-bis-(3,5-dicarb-oxy-benzoato-κO)zinc octa-hydrate. Acta Crystallogr Sect E Struct Rep Online (2012) 1.07
Structure-based prediction of transcription factor binding sites using a protein-DNA docking approach. Proteins (2008) 1.07
S-adenosyl-L-methionine attenuates oxidative stress and hepatic stellate cell activation in an ethanol-LPS-induced fibrotic rat model. Shock (2008) 1.07
Regulation of UHRF1 by miR-146a/b modulates gastric cancer invasion and metastasis. FASEB J (2013) 1.06
Autoimmune hepatitis triggered by statins. J Clin Gastroenterol (2006) 1.06
Multiple Cytochrome P450 genes: their constitutive overexpression and permethrin induction in insecticide resistant mosquitoes, Culex quinquefasciatus. PLoS One (2011) 1.06
Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells. Liver Int (2008) 1.05